Untitled | 合法藥品大搜索

2016年5月31日 — K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and ... drugs dose adjustment ... Mitiglinide ( Glufast. Read More

elimination half-life for mitiglinide in plasma was ob- served in patients with chronic renal failure and it may cause hypoglycemia. (See PHARMACOKINET-. Read More

由 M Abe 著作 · 2010 · 被引用 22 次 — diabetes and end-stage renal disease (ESRD) are lim- ited because a ... The average final dose of mitiglinide was 20.0 ± 8.6 mg daily. Mitiglinide was effective​ ... Read More

The glitinides (repaglinide; nateglinide; mitiglinide) are used for treating patients ... generally decrease as kidney function declines.16–19 Insulin doses must be ... Read More

由 M Abe 著作 · 2011 · 被引用 157 次 — Therapeutic options for patients with type 2 diabetes and chronic kidney ... Repaglinide and mitiglinide are rapid- and short-acting insulinotropic SU ... by hypoglycemia and are administered without dose adjustments in Read More

The average final dose of mitiglinide was 20.0 +/- 8.6 mg daily. Mitiglinide ... Male​; Middle Aged; Renal Dialysis*/methods; Treatment Outcome ..., Mitiglinide: a ... Read More

2007年3月30日 — Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ... Read More

2021年4月15日 — In the present study, we used mitiglinide because it has been reported to be safe, even in patients with renal failure. 23 Because of the rapid ... Read More